Our community

Organon is a new member of the Biosimilars Forum

This coalition aims to promote awareness of and access to biosimilar medicines

July 12, 2021

Share this article

article hero thumbnail

Organon has been announced as a new member of the Biosimilars Forum: an organization with the intent to advance biosimilars in the United States by expanding access and availability of biologic medicines and providing biosimilars education and advocacy programs.

Biosimilars are biologic medicines that are highly similar, but not identical, to biologic medicines that are already approved.1 Biologics are created using living organisms such as yeast, bacteria, or cells from animals or plants, and are highly complex to manufacture.1

In 2019, biologic products accounted for 43% of all US medicine spending.2 Through adoption of biosimilars, it is estimated the health care system could save $104 billion from 2020 – 2024.2 Biosimilars also enable multiple sourcing options for prescribers, and may allow for increased access to biologic treatments.1 What generics were to the US health care system in the 20th century is what biosimilars have the potential to become in the 21st century.3 The Biosimilars Forum supports public policy legislation supporting increased uptake of biosimilars.

At Organon, we are committed to broadening the reach and realizing the greater potential of biosimilars for the healthcare system. To that end, we look forward to working with this important organization on our shared goals.

1. Biosimilars Patient Materials. Food and Drug Administr ation. Accessed at https://www.fda.gov/drugs/biosimilars/patient-materials. Accessed July 1, 2021.

2. Aitken M, Kleinrock M, Muñoz E. Biosimilars in the United States 2020–2024: Competition, Savings, and Sustainability. IQVIA Institute for Human Data Science report. September 29, 2020. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024. Accessed July 1, 2021.

3. US Food and Drug Administration. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s biosimilars action plan. July 18, 2018. https://www.fda.gov/news-events/press-announcements/remarks-fda-commissioner-scott-gottlieb-md-prepared-delivery-brookings-institution-release-fdas. Accessed July 1, 2021.